Dataset Information


GPRC5A facilitates cell proliferation and bone metastasis of prostate cancer.

ABSTRACT: Prostate cancer is a high frequent disease. Early stage prostate cancer can be cured with high probability by early treatment, but hormone refractory prostate cancer and progressive prostate cancer is poor prognosis. Orphan GPCRs have the potential to become a drug discovery target in various carcinomas, but there are few reports in prostate cancer and there are still many possibilities. By big data analysis, we focused on the biological properties of the prostate cancer cell line and found GPRC5A from Orphan GPCR as one of the regulators of prostate cancer development. GPRC5A knock out by genomic editing in PC3, proliferative ability and bone metastasis was markedly suppressed. In prostate cancer cells, GPRC5A inhibit phosphorylation of CREB and affected the expression of cell cycle related genes. GPRC5A is also involved in the establishment of bone metastases, and correlated with prostate cancer metastasis and prognosis. These dates suggest that GPRC5A facilitates cell proliferation and progression of prostate cancer and can be a target for new prognostic marker or drug discovery of prostate cancer. Overall design: mRNA profiles of wild type PC3-Luc cells and two GPRC5A knockout PC3-Luc cells were generated by deep sequencing, in triplicate, using Illumina Miseq.

INSTRUMENT(S): Illumina MiSeq (Homo sapiens)

ORGANISM(S): Homo Sapiens

SUBMITTER: Yuuki Imai  

PROVIDER: GSE121319 | GEO | 2019-07-16


Dataset's files

Action DRS
GSE121319_tmm_PC3_Control_vs_GPRC5AKO.txt.gz Txt
Items per page:
1 - 1 of 1
altmetric image


GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer.

Sawada Yuichiro Y   Kikugawa Tadahiko T   Iio Hiroyuki H   Sakakibara Iori I   Yoshida Shuhei S   Ikedo Aoi A   Yanagihara Yuta Y   Saeki Noritaka N   Győrffy Balázs B   Kishida Takeshi T   Okubo Yoichiro Y   Nakamura Yoshiyasu Y   Miyagi Yohei Y   Saika Takashi T   Imai Yuuki Y  

International journal of cancer 20190722 5

The prognosis of patients with progressive prostate cancers that are hormone refractory and/or have bone metastasis is poor. Multiple therapeutic targets to improve prostate cancer patient survival have been investigated, including orphan GPCRs. In our study, we identified G Protein-Coupled Receptor Class C Group 5 Member A (GPRC5A) as a candidate therapeutic molecule using integrative gene expression analyses of registered data sets for prostate cancer cell lines. Kaplan-Meier analysis of TCGA  ...[more]

Similar Datasets

| S-EPMC3743748 | BioStudies
| S-EPMC6051198 | BioStudies
| S-EPMC6330258 | BioStudies
| S-EPMC6292965 | BioStudies
| S-EPMC6691707 | BioStudies
| S-EPMC4996404 | BioStudies
| S-EPMC4688563 | BioStudies
| S-EPMC8011795 | BioStudies
| S-EPMC5485747 | BioStudies
| S-EPMC5601723 | BioStudies